M28 Capital Management’s TG Therapeutics TGTX Stock Holding History

M28 Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.85M	Hold	88,354	–	–	10.29%	3
2026 Q1	$2.94M	Sell	88,354 -73,246	-45%	-$2.18M	5.46%	3
2025 Q4	$4.82M	Hold	161,600	–	–	3.5%	3
2025 Q3	$5.84M	Hold	161,600	–	–	8.58%	3
2025 Q2	$5.82M	Hold	161,600	–	–	9.92%	3
2025 Q1	$6.37M	Hold	161,600	–	–	8.73%	2
2024 Q4	$4.86M	Hold	161,600	–	–	4.78%	2
2024 Q3	$3.78M	Hold	161,600	–	–	4.15%	5
2024 Q2	$2.87M	Hold	161,600	–	–	3.73%	9
2024 Q1	$2.46M	Sell	161,600 -55,000	-25%	-$876K	1.82%	9
2023 Q4	$3.7M	Hold	216,600	–	–	3.06%	9
2023 Q3	$1.81M	Buy	216,600 +74,100	+52%	+$1.03M	2.08%	10
2023 Q2	$3.54M	Sell	142,500 -197,000	-58%	-$5.09M	4.68%	7
2023 Q1	$5.11M	Buy	339,500 +235,100	+225%	+$3.57M	5.77%	4
2022 Q4	$1.24M	Sell	104,400 -234,400	-69%	-$1.7M	1.18%	13
2022 Q3	$2.01M	Sell	338,800 -387,400	-53%	-$2.54M	2.09%	10
2022 Q2	$3.09M	Sell	726,200 -321,700	-31%	-$2.01M	3.46%	8
2022 Q1	$9.97M	Buy	1,047,900 +520,900	+99%	+$6.03M	9.16%	6
2021 Q4	$10M	Buy	+527,000	New	+$13.7M	7.82%	6

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

M28 Capital Management's TGTX Position: Q2 2026 in Review

M28 Capital Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 88,354 shares worth $4.85M. The position accounts for 10.29% of the portfolio, ranked #3.

M28 Capital Management first reported a position in TGTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $10M in Q4 2021. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

M28 Capital Management held 88,354 shares of TG Therapeutics worth $4.85M as of Q2 2026.
M28 Capital Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 10.29% of M28 Capital Management's portfolio in Q2 2026, its #3 holding.
M28 Capital Management first reported a position in TG Therapeutics in Q4 2021 and has held it in 19 quarters since.
M28 Capital Management's TG Therapeutics position peaked at $10M in Q4 2021.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on M28 Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.